Nature-derived drug discovery.
Pangea harnesses the tools of modern drug discovery to develop nature-inspired therapeutics for unmet patient needs. We have the ability to execute and deliver, with a scalable and diversified platform operating model and an experienced team.
Pushing for a better tomorrow.
We have 5 preclinical lead compounds excluding discovery pipeline across 4 programs. Our programs are developing drugs to target inflammation, autoimmune, psychiatric, neurodegenerative and neurological indications. Further growth of the platform will be supported by our proprietary PangeAI discovery engine.
There is meaningful potential to develop drugs inspired by nature given its co-evolution with human biology, vast chemical diversity, polypharmacology (multiple drug targets) and prior human use, an indicator of efficacy and safety.
Nature is one of the richest untapped sources of possible therapeutic compounds. Only less than 1% of nature's small molecules have been mapped and explored. Pangea remains conscious of the remaining 99% which could be explored at scale.
Pangea Botanica assembles uncorrelated programs across therapeutic areas, increasing the likelihood of successful commercialization. To date, Pangea comprises four development programs, Kanna Health, the OTT program, KT program and AH program.
Patients around the world have high unmet medical needs, with 52% of the population suffering from at least one chronic disease, and 95% of rare diseases having no approved treatment. Our four development programs research and trial different bioactive compounds across a range of indications.
We send our newsletter regularly, sharing news and trends around Pangea Botanica, its ecosystem of operating companies and our research space.